Table 4

Test characteristics of different FIT screening strategies (cut-off value, 50 ng Hb/mL) (adapted from van Roon et al 83)

Screening StrategyPRPPVNNScopeDetection rateNNScreen
n% (95% CI)Advanced neoplasia, % (95% CI)CRC, % (95% CI)Advanced adenoma, % (95% CI)Advanced neoplasia,
n
CRC, nAdvanced neoplasiaCRCAdvanced Neoplasia,
n
CRC, n
n% (95% CI)n% (95% CI)
One-sample FIT screening2418.1 (7.2 to 9.1)41 (35 to 48)7 (4 to 11)34 (28 to 40)2.414.1933.1 (2.5 to 3.8)160.5 (0.3 to 0.8)32186
Two-sample FIT (≥1 positive)23912.8 (11.4 to 14.4)*34 (28 to 40)5 (3 to 9)29 (23 to 35)2.918.5764.1 (3.3 to 5.1)120.6 (0.3 to 1.1)25156
Two-sample FIT (mean of both tests)19010.1 (8.8 to 11.5)*39 (32 to 46)7 (2 to 7)32 (26 to 39)2.614.8693.7 (2.9 to 4.7)120.6 (0.3 to 1.1)27156
Two-sample FIT (both positive)945.0 (4.1 to 6.1)*52 (42 to 62)10 (5 to 18)42 (32 to 53)1.99.8462.5 (1.9 to 3.3)90.5 (0.3 to 1.0)41208
  • *p<0.05 compared with 1-sample FIT screening.

  • Advanced adenoma, adenoma >25% villous component and/or high-grade dysplasia; advanced neoplasia, CRC and advanced adenoma; CRC, colorectal cancer; FIT, faecal immunochemical tests; NNScope, number of colonoscopies that needs to be performed to find one screenee with an advanced neoplasia; NNScreen, number of individuals that need to be screened to find one individual with an advanced neoplasia; PPV, positive predictive value; PR, positivity rate.